ClinicalTrials.gg
TerminatedNCT00751166Updated Aug 15, 2024

A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)

A Phase 4 interventional study of Desloratadine and Cetirizine in Urticaria, sponsored by Organon and Co. Terminated. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Why this study was terminated
Study could not be re-supplied with study medication in a timely manner.

From the registry’s dates

  • Registered 4 years 6 months after the study started (first participant enrolled Mar 2004, registered Sep 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing desloratadine in Urticaria — none open to participants now, none under way, none of them phase 3. desloratadine · Urticaria.

Enrollment
5th of 10
149 · median 139
Started
2004
with 1 other
Phase 4
7 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
6 of 10
Organon and Co

Among the 10 studies testing desloratadine in Urticaria, this one is the 5th largest by enrollment, is one of 2 that started in 2004, is one of 7 in phase 4, and was the 3rd registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 20 are open to participants now.

Browse Urticaria studies →

Open to participants now

None of the 10 studies testing desloratadine in Urticaria is open now. The open studies under Urticaria, anywhere →

Where they have run

About desloratadine

desloratadine: first FDA approval 2001 (CLARINEX), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing desloratadine in Urticaria as a file.
02

Study summary

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.

03

Conditions studied

  • Urticaria

Browse trials for

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have demonstrated their willingness to participate in the study and comply with its procedures by signing a written . For pediatric patients, the parent or legal guardian was to have signed a written informed consent.
  • Be between 12 and 70 years of age, of either sex and any race.
  • Have had signs and symptoms of CIU for at least 6 weeks prior to the Screening Visit.
  • Have been experiencing a current flare of their CIU of at least 3 weeks prior to the Baseline Visit. Hives were to have been present for at least 3 days per week during the current flare prior to the Baseline Visit.
  • Have an overall condition of CIU that was at least of "moderate" severity (minimum score of 2) at both Screening and Baseline Visits.
  • Have at least a moderately severe pruritus score (minimum score of 2) and hives (minimum score of 1) present at Screening.
  • Have, at Baseline, a total pruritus score of 14 or greater for the sum of AM and PM (reflective) diary scores for the 3 days prior to Baseline and the AM diary score on Day 1.
  • Understand and be able to adhere to the dosing and visit schedules, and agree to assess and record their symptom severity scores, medication times,concomitant medications, and adverse events accurately and consistently in a daily diary.
  • Be in general good health and free of any disease (other than CIU) that would have interfered with study evaluations.
  • If female and of , have had a negative urine (hCG) pregnancy test at the time of Baseline (Visit 2).
  • Female subjects of childbearing potential were to be counseled in the appropriate use of while in the study. They were to be using a medically accepted method of birth control, for example: double barrier method, oral contraceptive, Depo-Provera®, or Norplant®, prior to Baseline and during the study. Women who were not sexually active were to agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study. If the subject had had a tubal ligation or was using an intra-uterine device, or if the husband/partner had had a vasectomy, another method was to be used.

Exclusion criteria

Exclusion Criteria:

  • Had asthma requiring chronic use of inhaled or systemic .
  • Had been unresponsive to antihistamine treatment in the past.
  • Had a history of allergies to more than two classes of medication or who were allergic to or unable to tolerate antihistamines.
  • Had used any drug in the last 30 days prior to Baseline.
  • Had food or drug allergies manifested as skin reactions. Subjects with urticaria that was primarily due to physical urticaria or other known etiology.
  • If female, were pregnant or nursing.
  • Had a history of to the study drug or its .
  • Were family members of the investigational study staff involved with this study.
  • Had previously been randomized into the study.
  • Had current evidence of hematopoietic, cardi distribution, metabolism, or excretion of the study medication or with the subject's ability to reliably complete the diary card.
  • Were morbidly obese ( >= 35, as described in Appendix 6 of the protocol)
  • Had a compromised ability to provide .
  • Had a history of non-compliance with medications or treatment protocols.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    1

    Desloratadine

    Drug: Desloratadine

  • Active comparator
    2

    Cetirizine

    Drug: Cetirizine

  • Placebo comparator
    3

    placebo

    Drug: placebo

Interventions

  • Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days

  • Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days

  • Drugplacebo

    placebo once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Compare the efficacy of the study treatments with respect to the change from Baseline in the average AM/PM 12-hour reflective pruritus severity score (diary recordings)

    Time frame: After the first 7 days of treatment

Secondary outcomes

  1. Joint physician-patient evaluations ("now") of: overall condition of the CIU and overall global therapeutic response.

    Time frame: At treatment days 14 and 28 (Visit 3 and 4)

  2. Average AM/PM "reflective" diary scores over treatment days 1-7, 8-14, 15-21 and 22-28 for: severity of pruritus; number of hives; size of largest hives; total symptom score (pruritus, number of hives, size of the largest hives)

    Time frame: Days 7, 14, 21 and 28

  3. Average AM/PM "reflective" diary scores over treatment days 1-7, 8-14, 15-21 and 22-28 for: subject-evaluated CIU interference with sleep (AM) and interference with daily activities (PM)

    Time frame: Days 7, 14, 21 and 28

  4. Adverse Events

    Time frame: End of Trial

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2004 to primary completion in May 2005, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2008
First posted
Sep 11, 2008
StartActual
Mar 1, 2004
Primary completionActual
May 1, 2005
CompletionActual
May 1, 2005
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00751166
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 11, 2008
Start date
Mar 1, 2004
Primary completion
May 1, 2005
Completion
May 1, 2005
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion